Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drug

After accounting for individual risk factors, patients taking Mounjaro were 76% more likely to lose at least 5% of their body weight, more than twice as likely to lose at least 10%, and more than three times as likely to lose at least 15%.

The best way to compare the two weight-loss drugs is through a head-to-head clinical trial, and noted that no such trial has yet been completed.

Read at Fast Company